Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Sasha M. Lupichuk"'
Publikováno v:
Current Oncology, Vol 28, Iss 209, Pp 2270-2280 (2021)
Current Oncology
Volume 28
Issue 3
Pages 209-2280
Current Oncology
Volume 28
Issue 3
Pages 209-2280
In this analysis, we describe population-based outcomes for first-line treatment with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) combined with an aromatase inhibitor (AI). All patients who were prescribed CDK4/6i + AI from January 2016 through
Publikováno v:
Current Oncology, Vol 28, Iss 109, Pp 1137-1142 (2021)
Current Oncology
Current Oncology
Uncertainty exists around the need to include an anthracycline if taxane-based adjuvant chemotherapy is being used for human epidermal growth factor receptor-2 (HER2) negative and axillary lymph node negative (LNN) breast cancer. We identified all pa
Publikováno v:
Can J Surg
In 2012, the American Society of Clinical Oncology (ASCO) released a Choosing Wisely Top Five list that included a recommendation against ordering advanced imaging tests to screen for metastases among asymptomatic patients with early breast cancer. O
Autor:
Lisa Barbera, Shiying Kong, Che Hsuan David Wu, Yuan Xu, Sasha M. Lupichuk, Jeffrey Q. Cao, May Lynn Quan
Publikováno v:
Current Oncology
Volume 28
Issue 6
Pages 375-4431
Current Oncology, Vol 28, Iss 375, Pp 4420-4431 (2021)
Volume 28
Issue 6
Pages 375-4431
Current Oncology, Vol 28, Iss 375, Pp 4420-4431 (2021)
Breast cancer patients receiving adjuvant chemotherapy are at increased risk of acute care use. The incidence of emergency department (ED) visits and hospitalizations (H) have been characterized in other provinces but never in Alberta. We conducted a
Autor:
Patricia A. Tang, Zachary William Neil Veitch, Derek Tilley, Domen Ribnikar, Omar Farooq Khan, Douglas A. Stewart, Xanthoula Kostaras, Sasha M. Lupichuk, Karen King
Publikováno v:
Journal of the National Comprehensive Cancer Network. 17:957-967
Background: Reductions in adjuvant chemotherapy dose Patients and Methods: Women with stage I–III, hormone receptor–positive/negative, HER2-negative breast cancer treated with adjuvant FEC-D chemotherapy from 2007 through 2014 in Alberta, Canada,
Autor:
Omar Farooq Khan, Karen King, Xanthoula Kostaras, Patricia A. Tang, Derek Tilley, Zachary William Neil Veitch, Domek Ribnikar, Sasha M. Lupichuk
Publikováno v:
Journal of the National Comprehensive Cancer Network. 17:47-56
Background: Comparative real-world outcomes for patients with HER2-positive (HER2+) breast cancer receiving adjuvant trastuzumab outside of clinical trials are lacking. This study sought to retrospectively characterize outcomes for patients with node
Autor:
Kathleen Reynolds, Susan Horsman, Sasha M. Lupichuk, Cynthia Kwok, Devesh Oberoi, Nicole Culos-Reed, Linda E. Carlson, Yong Li, Cindy Railton, Michael Speca, Anil A. Joy, Janine Giese-Davis, Karen Marie King
Publikováno v:
BMC medical research methodology. 22(1)
Background With advances in cancer diagnosis and treatment, women with early-stage breast cancer (ESBC) are living longer, increasing the number of patients receiving post-treatment follow-up care. Best-practice survivorship models recommend transiti
Publikováno v:
Journal of palliative medicine. 24(6)
Purpose: Guidelines suggest that advance care planning (ACP) and goals-of-care discussions should be conducted for patients with advanced cancer early in the course of their disease. A recent audit of our health system found that these discussions we
Autor:
Abdulla Al-Rashdan, Sasha M. Lupichuk, Carla P Amaro, Jeffrey Q. Cao, Michael Roumeliotis, Sarah Quirk, Lisa Barbera
Publikováno v:
Radiotherapy and Oncology. 163:S39
Publikováno v:
Journal of Clinical Oncology. 39:e12569-e12569
e12569 Background: Biosimilars are defined as medical products that contains a version of the active substance with similar biological characteristics, efficacy, and safety as the original product. Differences however, exist between biosimilars and t